Literature DB >> 26436127

Safety of inoculation of bovine parainfluenza virus 3 as potential vaccine vector in pigs.

Feng-Xue Wang1, Ying Liu1, Hong-Wei Zhu1, Xing Liu1, Yong Yang1, Na Sun1, Shi-Peng Cheng1, Yong-Jun Wen1.   

Abstract

Bovine parainfluenza virus 3 (BPIV3) is one of the most important respiratory pathogens in cattle. One BPIV3, named NM09, was isolated from cattle suffering from severe respiratory diseases in 2009. BPIV3 is a potential recombinant vaccine vector. To investigate whether NM09 can infect pigs and determine BPIV3 defense in these animals, BPIV3 antibody-free pigs were inoculated intramuscularly with the BPIV3 NM09 strain in a continuous passage. Clinical signs were observed each day after inoculation. Viral nucleic acid was detected in nasal and anal secretions. Results showed that virus-inoculated pigs displayed few observable clinical signs related to respiratory diseases. The antibody was identified, but the virus could not be detected in the second continuous passage in pigs. Thus, BPIV3 is a potential vaccine vector for genetic engineering.

Entities:  

Keywords:  Bovine parainfluenza virus; Potential vaccine vector; Safety

Year:  2015        PMID: 26436127      PMCID: PMC4585058          DOI: 10.1007/s13337-015-0250-3

Source DB:  PubMed          Journal:  Virusdisease        ISSN: 2347-3584


  13 in total

1.  Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector.

Authors:  A A Haller; T Miller; M Mitiku; K Coelingh
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  Molecular characterization of a Korean bovine parainfluenza virus type 3 isolate.

Authors:  Jae-Ku Oem; Eun-Yong Lee; Kyoung-Ki Lee; Seong-Hee Kim; Myoung-Heon Lee; Bang-Hun Hyun
Journal:  Vet Microbiol       Date:  2012-10-22       Impact factor: 3.293

3.  Infection of the upper respiratory tract of hamsters by the bovine parainfluenza virus type 3 BN-1 strain expressing enhanced green fluorescent protein.

Authors:  Takashi Ohkura; Moeko Minakuchi; Mami Sagai; Takehiro Kokuho; Misako Konishi; Ken-Ichiro Kameyama; Kaoru Takeuchi
Journal:  Virology       Date:  2014-12-24       Impact factor: 3.616

4.  Bovine parainfluenza virus type 3 (PIV3) expressing the respiratory syncytial virus (RSV) attachment and fusion proteins protects hamsters from challenge with human PIV3 and RSV.

Authors:  Aurelia A Haller; Misrach Mitiku; Mia MacPhail
Journal:  J Gen Virol       Date:  2003-08       Impact factor: 3.891

5.  Phylogenetic analysis of the bovine parainfluenza virus type 3 from cattle herds revealing the existence of a genotype A strain in China.

Authors:  Yong-Jun Wen; Xin-Chuan Shi; Feng-Xue Wang; Wei Wang; Shu-Qin Zhang; Guo Li; Ni Song; Li-Zhi Chen; Shi-Peng Cheng; Hua Wu
Journal:  Virus Genes       Date:  2012-08-26       Impact factor: 2.332

6.  Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV). A meeting report of the WHO Programme for Vaccine Development.

Authors:  J E Crowe
Journal:  Vaccine       Date:  1995-03       Impact factor: 3.641

7.  Molecular characterization of glycoprotein genes and phylogenetic analysis of two swine paramyxoviruses isolated from United States.

Authors:  Dan Qiao; Bruce H Janke; Subbiah Elankumaran
Journal:  Virus Genes       Date:  2009-04-01       Impact factor: 2.332

8.  Identification of two distinct bovine parainfluenza virus type 3 genotypes.

Authors:  Paul Francis Horwood; Jennifer Lillian Gravel; Timothy John Mahony
Journal:  J Gen Virol       Date:  2008-07       Impact factor: 3.891

9.  Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children.

Authors:  Ruth A Karron; Bhagvanji Thumar; Elizabeth Schappell; Sonja Surman; Brian R Murphy; Peter L Collins; Alexander C Schmidt
Journal:  Vaccine       Date:  2011-12-14       Impact factor: 3.641

10.  Characterization of bovine parainfluenza virus type 3.

Authors:  H Shibuta; T Kanda; A Adachi; Y Yogo
Journal:  Microbiol Immunol       Date:  1979       Impact factor: 1.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.